Home » Business, Manufacturing & Industry, Marketing & Sales, Pharmaceuticals & Biotech, World » Alzheimer’s Therapeutics Market is Expected to Reach $6.4 Billion, Globally, by 2024 – Hexa Reports
“Get key Market Research Reports and Insightful Company Profiles”
The cholinesterase inhibitors segment was dominant in 2013 but lost hold on the market till 2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor for decline in market share.

The global alzheimer’s therapeutics market is expected to reach USD 6.4 billion in 2024, according to a new report by Grand View Research. Some primary factors driving the market growth includes rising government initiatives in order to raise awareness levels among people.

Growing knowledge about the Alzheimer’s disease (AD) and its high prevalence and incidence in developing economies are few of the major drivers supporting the market growth. Several governments, nonprofit, and private organizations worldwide are actively engaged in increasing people’s awareness regarding progressive AD, such as Alzheimer’s Association, the Alzheimer’s Society of Canada, Alzheimer’s Europe organization, and various other small organizations.

Furthermore, the increased government funding for providing better care and support to the people with partial dementia is another important factor anticipated to enlarge market growth. For instance, organizations like Florida Department of Health, the National Institute of Health, and Alzheimer’s Association in partnership with other private and government organizations provide funds to the research centers.

Browse Detail Report With TOC @ http://www.hexareports.com/report/alzheimer-s-therapeutics-market/details

The presence of various pipeline drugs is anticipated to provide the market with potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai

Moreover, novel therapeutics with minimal dosage requirement has been introduced resulting in cost-effective alternatives, which is further expected to boost the market growth. For instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28 mg requires to be administered once in a day.

Further key findings from the study suggest:

The cholinesterase inhibitors segment was dominant in 2013 but lost hold on the market till 2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor for decline in market share.

Exelon transdermal patch is estimated to lose exclusivity in 2019. It is a highly prescribed drug for the treatment of mild to moderate AD, which contributed toward its revenue generation in 2015.

N-methyl-D-aspartate receptor antagonist, on the other hand, is expected to witness a significant growth of around 16.0% over the forecast period owing to introduction of extended relase formulation of Namenda.

Request A Sample copy of This Report @ http://www.hexareports.com/sample/159441

Other drug therapies such as monocloclonal antibodies and drugs targeting Tau proteins are in being studied in latter phases of the clinical trials. Presence of a strong of pipeline drugs for target disease are attributing toward fastest growth of these drugs

North America dominated the overall market in terms of revenue with share of over 33.0% in 2015, which is majorly facilitated by the availability of sophisticated healthcare facilities and infrastructure.

Some key players operating in this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG; Eisai Co. Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.; Actavis plc.; Forest Laboratories; and Teva Pharmaceuticals Industries Ltd.

Market players are expanding their product portfolio by developing and launching generic versions of drugs to sustain its market position. For instance, in 2015, Dr. Reddy’s Laboratories Ltd. and Mylan launched the generic version of Namenda (Forest laboratories – Actavis).

Related Reports:

Global Mitochondrial Disorders Genetic Testing Sales Market Report 2021:

Global Gaucher Disease Market Research Report 2021:

About Us:

Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Media Contact
Company Name: Hexa Reports
Contact Person: Ryan Shaw
Email: sales@hexareports.com
Phone: 1-800-489-3075
Address:Felton Office Plaza, 6265 Highway 9
City: Felton
State: California
Country: United States
Website: http://www.hexareports.com/report/alzheimer-s-therapeutics-market/details

Comments are closed.